Close



Mar 28, 2024 08:01AM
Mar 28, 2024 08:00AM
Mar 20, 2024 08:00AM
Nov 2, 2023 10:00AM
Oct 25, 2023 04:25PM
Sep 12, 2023 08:31AM
Sep 12, 2023 08:30AM Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Aug 3, 2023 04:05PM
Jun 28, 2023 06:45AM
Jun 28, 2023 06:45AM
May 3, 2023 04:05PM
Mar 9, 2023 08:13AM
Mar 8, 2023 08:03AM
Mar 8, 2023 08:00AM OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
Feb 23, 2023 04:05PM
Feb 9, 2023 07:05AM
Nov 8, 2022 04:05PM
Mar 1, 2022 06:00AM
Feb 24, 2022 04:05PM
Feb 15, 2022 11:09AM
Feb 15, 2022 11:08AM Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Feb 3, 2022 08:32AM
Feb 3, 2022 08:30AM
Jan 24, 2022 09:25AM
Jan 21, 2022 04:30PM
Jan 21, 2022 04:30PM
Dec 23, 2021 08:01AM
Dec 23, 2021 08:00AM OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
Dec 8, 2021 08:01AM
Dec 8, 2021 08:00AM
Oct 13, 2021 07:00AM
Sep 24, 2021 04:26PM
Sep 24, 2021 04:24PM
Aug 30, 2021 04:17PM
Jun 21, 2021 08:07AM OPKO Health (OPK) to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
Jun 21, 2021 08:03AM
Jun 17, 2021 07:06AM
Jun 17, 2021 07:00AM
May 24, 2021 07:31AM
May 24, 2021 07:30AM
Apr 28, 2021 04:05PM
Feb 26, 2021 06:39AM Pfizer (PFE) and OPKO (OPK) Announce EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Feb 26, 2021 06:30AM
Feb 18, 2021 04:05PM
Jan 4, 2021 06:46AM
Jan 4, 2021 06:45AM
Dec 29, 2020 09:27AM
Nov 20, 2020 04:45PM
Oct 8, 2020 06:49AM Pfizer (PFE) Phase 3 Once-Weekly Investigational Study of Somatrogon to Treat Children with GHD Met its Primary Endpoint
Oct 8, 2020 06:45AM

251,370 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All